NU576 Unit 3 Quiz Questions

NU576 Unit 3 Quiz Questions

Student Name

NU576 NP II – Primary Care of Women’s Health

Prof. Name:

Date

NU576 Unit 3 Quiz Questions

Perimenopause, menopause, hormone therapy, infertility evaluation, and common gynecologic conditions are key topics covered in Unit 3. The most tested concepts include the average age of perimenopause onset (35–40 years), menopause-related symptoms such as hot flashes and vaginal atrophy, hormone therapy considerations, contraindications, osteoporosis prevention, amenorrhea definitions, and infertility diagnostic testing. Understanding these concepts helps healthcare providers recognize normal reproductive transitions and provide evidence-based management.

Perimenopause and Menopause: Key Concepts

Average onset and common symptoms of perimenopause

Perimenopause is the transitional stage before menopause when ovarian hormone production begins to fluctuate. The average onset of perimenopause is typically between 35 and 40 years of age, although the timing varies among individuals.

Common findings during perimenopause include:

• Hot flashes and night sweats (vasomotor symptoms)

• Irregular menstrual cycles

• Increased cycle variability

• Symptoms occurring before the onset of menstruation

• Changes in ovulation patterns

Hot flashes are among the most common menopausal symptoms and occur in approximately 60% to 80% of women during the menopausal transition.

Pregnancy is still possible during perimenopause because ovulation may continue, although it becomes increasingly unpredictable.

Menopause Hormone Therapy (HT)

Hormone therapy may be considered for women experiencing moderate to severe menopausal symptoms. Benefits and risks should always be evaluated based on individual health history.

Benefits of hormone therapy

Hormone therapy may:

• Reduce vasomotor symptoms such as hot flashes

• Help preserve bone density

• Improve symptoms of genitourinary syndrome of menopause

For women with an intact uterus, the progestin component of hormone therapy is prescribed to reduce the risk of endometrial hyperplasia and endometrial cancer caused by unopposed estrogen exposure.

Contraindications to hormone therapy

Absolute contraindications to postmenopausal hormone therapy include:

• Unexplained vaginal bleeding

• History of certain estrogen-sensitive cancers

• Active or previous thromboembolic disease in appropriate clinical situations

• Significant cardiovascular risks depending on individual assessment

Women with a history of deep vein thrombosis (DVT) and significant vasomotor symptoms may require nonhormonal treatment options.

Nonhormonal Management of Hot Flashes

For women who cannot take hormone therapy, several medications have demonstrated effectiveness.

Effective alternatives include:

• Paroxetine

• Venlafaxine (Effexor)

• Sertraline (Zoloft)

• Gabapentin

Clonidine is generally less preferred because of limited effectiveness and a higher likelihood of adverse effects.

Genitourinary Syndrome of Menopause and Vaginal Changes

Estrogen deficiency after menopause can lead to atrophic vaginitis, also called genitourinary syndrome of menopause.

Findings associated with estrogen deficiency

Common findings include:

• Vaginal dryness

• Vaginal irritation

• Dyspareunia (painful intercourse)

• Thin vaginal tissues

• Vaginal pH greater than 5

The highest concentration of estrogen receptors is found in the vulva, making this area particularly affected by estrogen decline.

Benefits of topical estrogen therapy

Low-dose vaginal estrogen can improve local symptoms and may:

• Reduce vaginal dryness

• Improve vaginal tissue health

• Decrease recurrent urinary tract infection (UTI) risk

For women taking systemic hormone therapy who continue to experience bothersome atrophic vaginitis symptoms, additional topical estrogen therapy may provide symptom relief.

Osteoporosis Prevention After Menopause

Loss of estrogen after menopause increases the risk of osteoporosis and bone fractures.

Medications used for osteoporosis prevention and treatment

Common medications include:

• Alendronate (Fosamax): A bisphosphonate commonly prescribed once weekly

• Raloxifene: A selective estrogen receptor modulator used for osteoporosis prevention and may reduce the risk of invasive breast cancer in appropriate patients

Menstrual Disorders: Amenorrhea

Amenorrhea refers to the absence of menstruation.

Primary amenorrhea

Primary amenorrhea is defined as:

• No menarche by age 15 years

• No menstruation by age 13 years when secondary sexual characteristics are absent

Secondary amenorrhea

Secondary amenorrhea is defined as:

• Absence of menstruation for more than 3 months (three cycles) in individuals with previously regular cycles

• Absence of menstruation for 6 months in individuals with previously irregular cycles

Dysmenorrhea

Dysmenorrhea is pelvic pain associated with menstruation.

Common management strategies include:

• Nonsteroidal anti-inflammatory drugs (NSAIDs)

• Exercise

• Heat therapy, such as a heating pad

Infertility Evaluation and Diagnostic Testing

Infertility evaluation involves assessing ovulation, reproductive anatomy, and possible structural abnormalities.

Ovulation-related testing

Ultrasonography performed around ovulation helps evaluate:

• Pelvic structures

• Follicular development

• Endometrial thickness

• Possible abnormalities affecting fertility

Additional infertility tests

A hysterosalpingogram (HSG) is usually scheduled 2 to 5 days after menstruation to evaluate uterine shape and fallopian tube patency while avoiding the possibility of disrupting an early pregnancy.

Laparoscopy is commonly scheduled early in the menstrual cycle to evaluate pelvic anatomy and conditions such as endometriosis.

Unit 3 Quiz Review: High-Yield Facts

• Perimenopause commonly begins between ages 35 and 40.

• Hot flashes occur in approximately 60% to 80% of women during menopause.

• Testosterone levels are not expected to be elevated during menopause.

• Progestin is added to hormone therapy to prevent endometrial hyperplasia.

• Pregnancy remains possible during perimenopause.

• Ovulation becomes more irregular during the menopausal transition.

• Menstruation does not immediately stop during perimenopause; cessation occurs at menopause.

• Soy, red clover, and other plant-based compounds are examples of phytoestrogens.

• Estrogen deficiency increases vaginal pH and contributes to atrophic changes.

References

American College of Obstetricians and Gynecologists. (2023). Hormone therapy for menopause. https://www.acog.org/womens-health/faqs/hormone-therapy-for-menopause

National Institute on Aging. (2024). What is menopause? National Institutes of Health. https://www.nia.nih.gov/health/menopause

NU576 Unit 3 Quiz Questions

North American Menopause Society. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767–794. https://doi.org/10.1097/GME.0000000000002028

American Society for Reproductive Medicine. (2021). Evaluation and treatment of infertility. https://www.asrm.org/topics/topics-index/infertility/

National Osteoporosis Foundation. (2023). Osteoporosis prevention and treatment. https://www.nof.org/